Precipio, Inc. filings document the public-company disclosures of a specialty cancer diagnostics issuer with Pathology Services and Products operations. Its Form 8-K reports include Regulation FD updates for shareholder calls and investor presentations, furnished financial results, and material-event disclosures related to corporate communications and operating performance.
The company’s proxy materials describe annual meeting procedures, stockholder voting matters, governance, and access to annual reporting materials. Other filings document capital-structure matters, including common stock activity and the termination of an at-the-market sales agreement, alongside formal exhibits and disclosures tied to Precipio’s diagnostics business and shareholder communications.
Form 144 notice for Precipio, Inc. (PRPO): A holder plans to sell 6,152 shares of Common stock through Morgan Stanley Smith Barney, with an aggregate market value of $123,384.51. The shares represent part of 1,619,584 shares outstanding and the proposed approximate sale date is 09/08/2025.
The shares were acquired on 04/15/2024 as board compensation and paid as compensation. The filer reports no sales in the past three months and certifies no undisclosed material information.
Precipio, Inc. filed a current report to disclose that it has terminated its Sales Agreement with A.G.P./Alliance Global Partners covering an at-the-market offering program for its common stock, effective September 2, 2025. After this termination, Precipio can no longer sell additional shares under that agreement.
From April 14, 2023 through September 2, 2025, the company sold 11,847 shares of common stock under the program, generating net proceeds of approximately $0.1 million after commissions and offering expenses. Precipio also issued a press release announcing the termination.
Precipio, Inc. furnished an updated investor presentation dated August 18, 2025, providing refreshed information for shareholders and other stakeholders. The presentation is available on the company’s investor relations website and replaces the prior version furnished on June 13, 2022.
The updated deck is included as Exhibit 99.1 to this current report, while the cover page interactive data file is identified as Exhibit 104. The company states that this information, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934, meaning it is not subject to Section 18 liabilities or automatically incorporated into other securities law filings.
Precipio, Inc. reported net sales of $5.65 million for the three months ended June 30, 2025, up from $4.44 million a year earlier, led by service revenue of $5.005 million versus $3.909 million. Gross profit for the quarter was $2.43 million compared with $1.72 million in the prior year. The company recorded net income of $74 thousand in the quarter versus a $1.22 million loss in Q2 2024; for the six months it reported a net loss of $810 thousand compared with a $3.30 million loss a year earlier. A material contributor to quarterly other income was a recorded Employee Retention Credit of approximately $789 thousand.
The balance sheet shows total assets of $18.82 million, cash of $1.13 million and an accumulated deficit of $103.3 million. Management discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months absent additional revenue or financing. Material items disclosed include purchase commitments of approximately $2.2 million, a CHC temporary funding balance of about $0.6 million to be repaid through January 2026, and customer concentration with one customer representing ~27% of net sales.